Connect with us

International

Inspirational women from UK Synchrotron launch major recruitment campaign to promote STEM careers at AAAS international science conference

Today, at the prestigious AAAS science conference in Washington DC, Diamond Light Source, the UK’s synchrotron science facility, will unveil plans for…

Published

on

Today, at the prestigious AAAS science conference in Washington DC, Diamond Light Source, the UK’s synchrotron science facility, will unveil plans for its biggest recruitment campaign since its inception 20 years ago. Dozens of new roles will be available in the coming year and some examples of the variety of STEM careers will be showcased and celebrated by an all-women line up from the Diamond team. This recruitment drive aims to ensure the facility has the knowledge and expertise required to help plan and deliver world leading science for the next decade and beyond

Credit: Diamond Light Source

Today, at the prestigious AAAS science conference in Washington DC, Diamond Light Source, the UK’s synchrotron science facility, will unveil plans for its biggest recruitment campaign since its inception 20 years ago. Dozens of new roles will be available in the coming year and some examples of the variety of STEM careers will be showcased and celebrated by an all-women line up from the Diamond team. This recruitment drive aims to ensure the facility has the knowledge and expertise required to help plan and deliver world leading science for the next decade and beyond

In the lead up to International Women’s Day (8th March), Diamond’s workshop will shine a light on career pathways in world-changing science. A panel of four women from Diamond will address how their work across science and engineering helps to address 21st century challenges from energy research to pandemic preparedness.  They will share their professional journeys and insights into their roles. Job roles range from scientists, engineers, software experts, technicians to professional roles all essential to enabling the most brilliant science performed by scientists at Diamond. 

Through part of the next decade, Diamond will deliver an upgrade programme called Diamond-II. To continue delivering the world-changing science that Diamond leads and enables, Diamond-II is a project that will deliver a new machine and new beamlines with a comprehensive series of upgrades to optics, detectors, sample environments, sample delivery capabilities and computing. 

The workshop panel will feature Dr Lorraine Bobb – Head of Diagnostics Group; Sarah Macdonell – Head of Beamline Systems Engineering; Dr Chidinma Okolo – Beamline Scientist at B24 and Dr Lucy Saunders – Beamline Scientist at I11. It will be chaired by Isabelle Boscaro-Clarke – Head of Impact, Communications and Engagement, with an interactive Q&A session facilitated by Molly Pekarik Fry – Web and Digital Content Manager. (Short biographies below)

UKRI announced last June a new investment of £81.5 million over the next three years in Diamond-II, which when complete will: 

  • open up new pathways for materials research and drug development. 
  • offer real-time insights into processes such as advanced manufacturing and the performance of next-generation batteries and much more as Diamond science permeates virtually all fields of research. 

Isabelle Boscaro-Clarke, Head of Impact, Communications and Engagement comments: “Diamond is preparing for its final stage bid for making this investment a reality and it is paramount that we secure the best people to join us in all of the roles that are becoming available. To this end, we have created an open talent pool for anyone interested to apply. All one has to do is register for a job alert”. 

“It will be an exciting time to join Diamond as we lay the foundations for the future of the facility. Currently 12 vacancies are open and dozens will be added over the coming months. We’re acting fast to ensure our preparations for the upgrade are progressing in line with the project plan. So, if you are looking for a place where you can make a difference, where 21st century global challenges are being addressed, there’s no better place to be.” 

To date, together with its 16,000 strong user community, Diamond has enabled ground-breaking scientific achievements, including: 

  • time-critical data and resources for improved public understanding of COVID-19; 
  • research of an enzyme that degrades plastic; 
  • a new synthetic vaccine for the virus causing foot-and-mouth disease. 

Andrea Ward, CEO and Director of Finance and Corporate Services concludes: 

“Diamond Light Source has established itself as a world-class synchrotron facility enabling research by leading academic and industrial groups in physical and life sciences. Diamond has pioneered a model of highly efficient and uncompromised infrastructure offered as a user-focussed service driven by technical and engineering innovation.” 

ENDS

Workshop AAAS link: https://aaas.confex.com/aaas/2023/meetingapp.cgi/Session/31000                                                          Chair: Isabelle Boscaro-Clarke – Head of Impact, Communications & Engagement                 Presenter: Molly Pekarik-Fry – Web & Digital Content Manager  

For further information please contact Diamond Communications: Lorna Campbell +44 7836 625999 or Isabelle Boscaro-Clarke +44 1235 778130   Diamond Light Source: www.diamond.ac.uk  Twitter: @DiamondLightSou    

Speaker Bios:  

Lorraine Bobb – Head of Diagnostics Group 

Lorraine found her passion in the field of Beam Diagnostics, and currently serves Diamond as Head of Diagnostics group, leading the operation of existing diagnostics and feedback systems as well as developing new state-of-the-art instrumentation. She completed her undergraduate MSci Physics degree at Royal Holloway, University of London (RHUL), and to gain a better understanding on career path possibilities in the field, she undertook a summer student placement within the Diagnostics group at Diamond. After finishing her degree, Lorraine went on to do a PhD at RHUL in beam diagnostics where she worked at CERN in Switzerland for 3 years (notably during the Higgs discovery) and undertook shifts with beam to test her new diagnostic prototype at the Cornell Electron Storage Ring, USA. Now as Head of the Diagnostics Group Lorraine leads a team of physicists, engineers, technicians and apprentices, who provide instruments that are effectively the ‘eyes and ears’ of the Diamond machine. They design, build, maintain and continually improve a variety of instrumentation on the accelerators and beamlines to ensure the delivery of high-quality beams for our scientific user community and their beamline experiments. With these instruments Diamond measures parameters of the electron and photon beams such as position, size, bunch length, charge and many more. They also implement feedback systems to allow us to control these parameters. 

Sarah Macdonell – Head of Beamline Systems Engineering Group 

Sarah Macdonell serves as Diamond’s Head of Beamline Systems Engineering Group Manager, where she manages a multi-disciplined beamline systems engineering team, enabling them to push the boundaries of technical possibility to improve Diamond’s delivery of world class science. Sarah completed her Bachelor’s degree in Mechanical engineer at Loughborough University in 2002, followed by completing her Master’s degree in Mechatronics in 2003. More recently Sarah has undertaken a Senior Leaders Master’s Degree Apprenticeship and has subsequently obtained an MBA in Leadership Practice. Prior to joining Diamond Sarah worked for over 9 years at Malvern Instruments, a global manufacturer and supplier of laboratory analytical instruments, notable for their work in the advancement of particle sizing technology. Sarah led the development and maintenance of the company Mechanical Engineering Strategy to improve and develop the discipline of mechanical engineering across the business. Sarah joined Diamond in July 2017 at Head of Beamline Systems Engineering and has broader responsibility for quality and resource management across the engineering group. Sarah played an active role in Diamond’s first ever synchrotron school back in 2018 for engineers, highlighting how basic as well as innovative engineering is vital to the successful science carried out in synchrotrons. The school’s goal was to give these engineers a good insight and grounding into many of the specialist technical issues that arise when designing, building and testing systems for light source facilities.  

Chidinma Okolo – Beamline Scientist B24  

Chidinma Okolo currently serves as Beamline Scientist on Diamond’s B24 beamline, which specialises in correlative cryo-imaging. Beamline B24 offers 3D imaging with soft X-ray tomography (cryoSXT) complemented by super resolution fluorescence structured illumination microscopy (cryoSIM). She graduated from the University of Nigeria, Nsukka, with a Bachelor of Science degree in Zoology (2011) and a Master of Science degree in Zoology (with specialization in Physiology) (2015). Chidinma worked for 3 years as an Assistant Lecturer at the University of Nigeria, Nsukka, before proceeding to New Zealand for her doctoral training. She completed her doctoral training at the University of Otago, New Zealand and was awarded her PhD in December 2019. Her thesis expanded existing knowledge on the implications of post-translational modifications on the diabetic heart, with focus on the cardiac ryanodine receptor. Thereafter, she found herself highly interested in the organisation of the cellular ultrastructure in response to biological or external stressors. Chidinma joined the team at beamline B24 in 2019, where she uses correlative light and X-ray microscopy to study structural changes within the cellular landscape with time. Her primary role is to use her array of knowledge and technical skills to drive instrument development, disseminate knowledge gathered from in-house and collaborative research as well as providing support to academic and industrial users at the beamline. 

Lucy Saunders – Beamline Scientist I11  

Lucy did her PhD in Structural Chemistry at the University of Bath which was jointly funded by Diamond, and currently serves as a Beamline Scientist on the I11 beamline at Diamond Light Source, specialising in chemical crystallography of microcrystalline powders. Before joining I11, Lucy was a Post-Doctoral Research Associate (PDRA) on beamline I19 at Diamond, with a focus on single crystal samples. Lucy has built up many years’ experience in diffraction at both neutron and synchrotron sources. Her role involves preparing the beamline for user experiments and during an experiment she provides support and advice to the scientists to help them get the best possible results from their beamtime. The role also gives the opportunity to work on in-house research projects such as the development of new and current sample environments as well as to build on her own research areas. Her research focuses on exploring proton transfer behaviour in multi component molecular crystals. She uses a combination of methods to do this including diffraction, spectroscopy and computational analysis. In some cases, proton transfer is coupled with a structural phase transition which may also lead to changes in material properties. 

Isabelle Boscaro-Clarke – Head of Impact, Communications & Engagement 

Isabelle is a strategist with over 25 years’ experience in leading science communications, as well as engagement activities within complex scientific organisations. Isabelle has worked for Diamond Light Source since 2003 and has embedded a strong programme of engagement activities at the heart of the facility. The facility welcomes some 7,000 visitors every year, allowing direct access to some of the most inspiring scientists, engineers, professional staff and researchers in the world. As a sociologist by academic background, she is a co-author along with Technopolis for the socio-economic impact study where she helped design new methodologies for the assessment of key performance indicators. She is at the helm of three key functions for Diamond – Impact, Corporate Communications and Engagement. With a user community of over 16,000 researchers, she’s overseen strong engagement programmes from the student programme to the delivery of scientific events. Prior to joining Diamond, Isabelle held a similar position at the National Physical Laboratory (NPL) , where she also acted as a consultant to the UK Government’s Small Business Service (SBS). 

Molly Pekarik-Fry – Web & Digital Content Manager 

Molly serves Diamond as Web & Digital Content Manager and is an experienced science and corporate communications professional, with a history of improving multi-channel digital solutions for technology and research facilities.  Diamond’s digital communications strategy connects our world-changing science facility with thousands of researchers and users, STEM professionals, and students, daily through a programme of agile web design and digital UX, and social media community building. With over a decade of corporate communications experience, Molly has helped deliver digital outreach for partners such as Microsoft, Google, LG Electronics, Casio Projectors, and more. 

About Diamond Light Source provides industrial and academic user communities with access to state-of-the-art analytical tools to enable world-changing science. Shaped like a huge ring, it works like a giant microscope, accelerating electrons to near light speeds, to produce a light 10 billion times brighter than the Sun, which is then directed off into 33 laboratories known as ‘beamlines’. In addition to these, Diamond offers access to several integrated laboratories including the world-class Electron Bio-imaging Centre (eBIC) and the Electron Physical Science Imaging Centre (ePSIC).    

Diamond serves as an agent of change, addressing 21st century challenges such as disease, clean energy, food security and more. Since operations started, more than 16,000 researchers from both academia and industry have used Diamond to conduct experiments, with the support of approximately 760 world-class staff. Almost 12,000 scientific articles have been published by our users and scientists.    

Funded by the UK Government through the Science and Technology Facilities Council (STFC), and by the Wellcome Trust, Diamond is one of the most advanced scientific facilities in the world, and its pioneering capabilities are helping to keep the UK at the forefront of scientific research.    

Diamond was set-up as an independent not for profit company through a joint venture, between the UKRI’s Science and Technology Facilities Council and one of the world’s largest biomedical charities, the Wellcome Trust – each respectively owning 86% and 14% of the shareholding.    


Read More

Continue Reading

Government

Trump “Clearly Hasn’t Learned From His COVID-Era Mistakes”, RFK Jr. Says

Trump "Clearly Hasn’t Learned From His COVID-Era Mistakes", RFK Jr. Says

Authored by Jeff Louderback via The Epoch Times (emphasis ours),

President…

Published

on

Trump "Clearly Hasn't Learned From His COVID-Era Mistakes", RFK Jr. Says

Authored by Jeff Louderback via The Epoch Times (emphasis ours),

President Joe Biden claimed that COVID vaccines are now helping cancer patients during his State of the Union address on March 7, but it was a response on Truth Social from former President Donald Trump that drew the ire of independent presidential candidate Robert F. Kennedy Jr.

Robert F. Kennedy Jr. holds a voter rally in Grand Rapids, Mich., on Feb. 10, 2024. (Mitch Ranger for The Epoch Times)

During the address, President Biden said: “The pandemic no longer controls our lives. The vaccines that saved us from COVID are now being used to help beat cancer, turning setback into comeback. That’s what America does.”

President Trump wrote: “The Pandemic no longer controls our lives. The VACCINES that saved us from COVID are now being used to help beat cancer—turning setback into comeback. YOU’RE WELCOME JOE. NINE-MONTH APPROVAL TIME VS. 12 YEARS THAT IT WOULD HAVE TAKEN YOU.”

An outspoken critic of President Trump’s COVID response, and the Operation Warp Speed program that escalated the availability of COVID vaccines, Mr. Kennedy said on X, formerly known as Twitter, that “Donald Trump clearly hasn’t learned from his COVID-era mistakes.”

“He fails to recognize how ineffective his warp speed vaccine is as the ninth shot is being recommended to seniors. Even more troubling is the documented harm being caused by the shot to so many innocent children and adults who are suffering myocarditis, pericarditis, and brain inflammation,” Mr. Kennedy remarked.

“This has been confirmed by a CDC-funded study of 99 million people. Instead of bragging about its speedy approval, we should be honestly and transparently debating the abundant evidence that this vaccine may have caused more harm than good.

“I look forward to debating both Trump and Biden on Sept. 16 in San Marcos, Texas.”

Mr. Kennedy announced in April 2023 that he would challenge President Biden for the 2024 Democratic Party presidential nomination before declaring his run as an independent last October, claiming that the Democrat National Committee was “rigging the primary.”

Since the early stages of his campaign, Mr. Kennedy has generated more support than pundits expected from conservatives, moderates, and independents resulting in speculation that he could take votes away from President Trump.

Many Republicans continue to seek a reckoning over the government-imposed pandemic lockdowns and vaccine mandates.

President Trump’s defense of Operation Warp Speed, the program he rolled out in May 2020 to spur the development and distribution of COVID-19 vaccines amid the pandemic, remains a sticking point for some of his supporters.

Vice President Mike Pence (L) and President Donald Trump deliver an update on Operation Warp Speed in the Rose Garden of the White House in Washington on Nov. 13, 2020. (Mandel Ngan/AFP via Getty Images)

Operation Warp Speed featured a partnership between the government, the military, and the private sector, with the government paying for millions of vaccine doses to be produced.

President Trump released a statement in March 2021 saying: “I hope everyone remembers when they’re getting the COVID-19 Vaccine, that if I wasn’t President, you wouldn’t be getting that beautiful ‘shot’ for 5 years, at best, and probably wouldn’t be getting it at all. I hope everyone remembers!”

President Trump said about the COVID-19 vaccine in an interview on Fox News in March 2021: “It works incredibly well. Ninety-five percent, maybe even more than that. I would recommend it, and I would recommend it to a lot of people that don’t want to get it and a lot of those people voted for me, frankly.

“But again, we have our freedoms and we have to live by that and I agree with that also. But it’s a great vaccine, it’s a safe vaccine, and it’s something that works.”

On many occasions, President Trump has said that he is not in favor of vaccine mandates.

An environmental attorney, Mr. Kennedy founded Children’s Health Defense, a nonprofit that aims to end childhood health epidemics by promoting vaccine safeguards, among other initiatives.

Last year, Mr. Kennedy told podcaster Joe Rogan that ivermectin was suppressed by the FDA so that the COVID-19 vaccines could be granted emergency use authorization.

He has criticized Big Pharma, vaccine safety, and government mandates for years.

Since launching his presidential campaign, Mr. Kennedy has made his stances on the COVID-19 vaccines, and vaccines in general, a frequent talking point.

“I would argue that the science is very clear right now that they [vaccines] caused a lot more problems than they averted,” Mr. Kennedy said on Piers Morgan Uncensored last April.

“And if you look at the countries that did not vaccinate, they had the lowest death rates, they had the lowest COVID and infection rates.”

Additional data show a “direct correlation” between excess deaths and high vaccination rates in developed countries, he said.

President Trump and Mr. Kennedy have similar views on topics like protecting the U.S.-Mexico border and ending the Russia-Ukraine war.

COVID-19 is the topic where Mr. Kennedy and President Trump seem to differ the most.

Former President Donald Trump intended to “drain the swamp” when he took office in 2017, but he was “intimidated by bureaucrats” at federal agencies and did not accomplish that objective, Mr. Kennedy said on Feb. 5.

Speaking at a voter rally in Tucson, where he collected signatures to get on the Arizona ballot, the independent presidential candidate said President Trump was “earnest” when he vowed to “drain the swamp,” but it was “business as usual” during his term.

John Bolton, who President Trump appointed as a national security adviser, is “the template for a swamp creature,” Mr. Kennedy said.

Scott Gottlieb, who President Trump named to run the FDA, “was Pfizer’s business partner” and eventually returned to Pfizer, Mr. Kennedy said.

Mr. Kennedy said that President Trump had more lobbyists running federal agencies than any president in U.S. history.

“You can’t reform them when you’ve got the swamp creatures running them, and I’m not going to do that. I’m going to do something different,” Mr. Kennedy said.

During the COVID-19 pandemic, President Trump “did not ask the questions that he should have,” he believes.

President Trump “knew that lockdowns were wrong” and then “agreed to lockdowns,” Mr. Kennedy said.

He also “knew that hydroxychloroquine worked, he said it,” Mr. Kennedy explained, adding that he was eventually “rolled over” by Dr. Anthony Fauci and his advisers.

President Donald Trump greets the crowd before he leaves at the Operation Warp Speed Vaccine Summit in Washington on Dec. 8, 2020. (Tasos Katopodis/Getty Images)

MaryJo Perry, a longtime advocate for vaccine choice and a Trump supporter, thinks votes will be at a premium come Election Day, particularly because the independent and third-party field is becoming more competitive.

Ms. Perry, president of Mississippi Parents for Vaccine Rights, believes advocates for medical freedom could determine who is ultimately president.

She believes that Mr. Kennedy is “pulling votes from Trump” because of the former president’s stance on the vaccines.

“People care about medical freedom. It’s an important issue here in Mississippi, and across the country,” Ms. Perry told The Epoch Times.

“Trump should admit he was wrong about Operation Warp Speed and that COVID vaccines have been dangerous. That would make a difference among people he has offended.”

President Trump won’t lose enough votes to Mr. Kennedy about Operation Warp Speed and COVID vaccines to have a significant impact on the election, Ohio Republican strategist Wes Farno told The Epoch Times.

President Trump won in Ohio by eight percentage points in both 2016 and 2020. The Ohio Republican Party endorsed President Trump for the nomination in 2024.

“The positives of a Trump presidency far outweigh the negatives,” Mr. Farno said. “People are more concerned about their wallet and the economy.

“They are asking themselves if they were better off during President Trump’s term compared to since President Biden took office. The answer to that question is obvious because many Americans are struggling to afford groceries, gas, mortgages, and rent payments.

“America needs President Trump.”

Multiple national polls back Mr. Farno’s view.

As of March 6, the RealClearPolitics average of polls indicates that President Trump has 41.8 percent support in a five-way race that includes President Biden (38.4 percent), Mr. Kennedy (12.7 percent), independent Cornel West (2.6 percent), and Green Party nominee Jill Stein (1.7 percent).

A Pew Research Center study conducted among 10,133 U.S. adults from Feb. 7 to Feb. 11 showed that Democrats and Democrat-leaning independents (42 percent) are more likely than Republicans and GOP-leaning independents (15 percent) to say they have received an updated COVID vaccine.

The poll also reported that just 28 percent of adults say they have received the updated COVID inoculation.

The peer-reviewed multinational study of more than 99 million vaccinated people that Mr. Kennedy referenced in his X post on March 7 was published in the Vaccine journal on Feb. 12.

It aimed to evaluate the risk of 13 adverse events of special interest (AESI) following COVID-19 vaccination. The AESIs spanned three categories—neurological, hematologic (blood), and cardiovascular.

The study reviewed data collected from more than 99 million vaccinated people from eight nations—Argentina, Australia, Canada, Denmark, Finland, France, New Zealand, and Scotland—looking at risks up to 42 days after getting the shots.

Three vaccines—Pfizer and Moderna’s mRNA vaccines as well as AstraZeneca’s viral vector jab—were examined in the study.

Researchers found higher-than-expected cases that they deemed met the threshold to be potential safety signals for multiple AESIs, including for Guillain-Barre syndrome (GBS), cerebral venous sinus thrombosis (CVST), myocarditis, and pericarditis.

A safety signal refers to information that could suggest a potential risk or harm that may be associated with a medical product.

The study identified higher incidences of neurological, cardiovascular, and blood disorder complications than what the researchers expected.

President Trump’s role in Operation Warp Speed, and his continued praise of the COVID vaccine, remains a concern for some voters, including those who still support him.

Krista Cobb is a 40-year-old mother in western Ohio. She voted for President Trump in 2020 and said she would cast her vote for him this November, but she was stunned when she saw his response to President Biden about the COVID-19 vaccine during the State of the Union address.

I love President Trump and support his policies, but at this point, he has to know they [advisers and health officials] lied about the shot,” Ms. Cobb told The Epoch Times.

“If he continues to promote it, especially after all of the hearings they’ve had about it in Congress, the side effects, and cover-ups on Capitol Hill, at what point does he become the same as the people who have lied?” Ms. Cobb added.

“I think he should distance himself from talk about Operation Warp Speed and even admit that he was wrong—that the vaccines have not had the impact he was told they would have. If he did that, people would respect him even more.”

Tyler Durden Mon, 03/11/2024 - 17:00

Read More

Continue Reading

International

There will soon be one million seats on this popular Amtrak route

“More people are taking the train than ever before,” says Amtrak’s Executive Vice President.

Published

on

While the size of the United States makes it hard for it to compete with the inter-city train access available in places like Japan and many European countries, Amtrak trains are a very popular transportation option in certain pockets of the country — so much so that the country’s national railway company is expanding its Northeast Corridor by more than one million seats.

Related: This is what it's like to take a 19-hour train from New York to Chicago

Running from Boston all the way south to Washington, D.C., the route is one of the most popular as it passes through the most densely populated part of the country and serves as a commuter train for those who need to go between East Coast cities such as New York and Philadelphia for business.

Veronika Bondarenko captured this photo of New York’s Moynihan Train Hall. 

Veronika Bondarenko

Amtrak launches new routes, promises travelers ‘additional travel options’

Earlier this month, Amtrak announced that it was adding four additional Northeastern routes to its schedule — two more routes between New York’s Penn Station and Union Station in Washington, D.C. on the weekend, a new early-morning weekday route between New York and Philadelphia’s William H. Gray III 30th Street Station and a weekend route between Philadelphia and Boston’s South Station.

More Travel:

According to Amtrak, these additions will increase Northeast Corridor’s service by 20% on the weekdays and 10% on the weekends for a total of one million additional seats when counted by how many will ride the corridor over the year.

“More people are taking the train than ever before and we’re proud to offer our customers additional travel options when they ride with us on the Northeast Regional,” Amtrak Executive Vice President and Chief Commercial Officer Eliot Hamlisch said in a statement on the new routes. “The Northeast Regional gets you where you want to go comfortably, conveniently and sustainably as you breeze past traffic on I-95 for a more enjoyable travel experience.”

Here are some of the other Amtrak changes you can expect to see

Amtrak also said that, in the 2023 financial year, the Northeast Corridor had nearly 9.2 million riders — 8% more than it had pre-pandemic and a 29% increase from 2022. The higher demand, particularly during both off-peak hours and the time when many business travelers use to get to work, is pushing Amtrak to invest into this corridor in particular.

To reach more customers, Amtrak has also made several changes to both its routes and pricing system. In the fall of 2023, it introduced a type of new “Night Owl Fare” — if traveling during very late or very early hours, one can go between cities like New York and Philadelphia or Philadelphia and Washington. D.C. for $5 to $15.

As travel on the same routes during peak hours can reach as much as $300, this was a deliberate move to reach those who have the flexibility of time and might have otherwise preferred more affordable methods of transportation such as the bus. After seeing strong uptake, Amtrak added this type of fare to more Boston routes.

The largest distances, such as the ones between Boston and New York or New York and Washington, are available at the lowest rate for $20.

Read More

Continue Reading

International

The next pandemic? It’s already here for Earth’s wildlife

Bird flu is decimating species already threatened by climate change and habitat loss.

I am a conservation biologist who studies emerging infectious diseases. When people ask me what I think the next pandemic will be I often say that we are in the midst of one – it’s just afflicting a great many species more than ours.

I am referring to the highly pathogenic strain of avian influenza H5N1 (HPAI H5N1), otherwise known as bird flu, which has killed millions of birds and unknown numbers of mammals, particularly during the past three years.

This is the strain that emerged in domestic geese in China in 1997 and quickly jumped to humans in south-east Asia with a mortality rate of around 40-50%. My research group encountered the virus when it killed a mammal, an endangered Owston’s palm civet, in a captive breeding programme in Cuc Phuong National Park Vietnam in 2005.

How these animals caught bird flu was never confirmed. Their diet is mainly earthworms, so they had not been infected by eating diseased poultry like many captive tigers in the region.

This discovery prompted us to collate all confirmed reports of fatal infection with bird flu to assess just how broad a threat to wildlife this virus might pose.

This is how a newly discovered virus in Chinese poultry came to threaten so much of the world’s biodiversity.

H5N1 originated on a Chinese poultry farm in 1997. ChameleonsEye/Shutterstock

The first signs

Until December 2005, most confirmed infections had been found in a few zoos and rescue centres in Thailand and Cambodia. Our analysis in 2006 showed that nearly half (48%) of all the different groups of birds (known to taxonomists as “orders”) contained a species in which a fatal infection of bird flu had been reported. These 13 orders comprised 84% of all bird species.

We reasoned 20 years ago that the strains of H5N1 circulating were probably highly pathogenic to all bird orders. We also showed that the list of confirmed infected species included those that were globally threatened and that important habitats, such as Vietnam’s Mekong delta, lay close to reported poultry outbreaks.

Mammals known to be susceptible to bird flu during the early 2000s included primates, rodents, pigs and rabbits. Large carnivores such as Bengal tigers and clouded leopards were reported to have been killed, as well as domestic cats.

Our 2006 paper showed the ease with which this virus crossed species barriers and suggested it might one day produce a pandemic-scale threat to global biodiversity.

Unfortunately, our warnings were correct.

A roving sickness

Two decades on, bird flu is killing species from the high Arctic to mainland Antarctica.

In the past couple of years, bird flu has spread rapidly across Europe and infiltrated North and South America, killing millions of poultry and a variety of bird and mammal species. A recent paper found that 26 countries have reported at least 48 mammal species that have died from the virus since 2020, when the latest increase in reported infections started.

Not even the ocean is safe. Since 2020, 13 species of aquatic mammal have succumbed, including American sea lions, porpoises and dolphins, often dying in their thousands in South America. A wide range of scavenging and predatory mammals that live on land are now also confirmed to be susceptible, including mountain lions, lynx, brown, black and polar bears.

The UK alone has lost over 75% of its great skuas and seen a 25% decline in northern gannets. Recent declines in sandwich terns (35%) and common terns (42%) were also largely driven by the virus.

Scientists haven’t managed to completely sequence the virus in all affected species. Research and continuous surveillance could tell us how adaptable it ultimately becomes, and whether it can jump to even more species. We know it can already infect humans – one or more genetic mutations may make it more infectious.

At the crossroads

Between January 1 2003 and December 21 2023, 882 cases of human infection with the H5N1 virus were reported from 23 countries, of which 461 (52%) were fatal.

Of these fatal cases, more than half were in Vietnam, China, Cambodia and Laos. Poultry-to-human infections were first recorded in Cambodia in December 2003. Intermittent cases were reported until 2014, followed by a gap until 2023, yielding 41 deaths from 64 cases. The subtype of H5N1 virus responsible has been detected in poultry in Cambodia since 2014. In the early 2000s, the H5N1 virus circulating had a high human mortality rate, so it is worrying that we are now starting to see people dying after contact with poultry again.

It’s not just H5 subtypes of bird flu that concern humans. The H10N1 virus was originally isolated from wild birds in South Korea, but has also been reported in samples from China and Mongolia.

Recent research found that these particular virus subtypes may be able to jump to humans after they were found to be pathogenic in laboratory mice and ferrets. The first person who was confirmed to be infected with H10N5 died in China on January 27 2024, but this patient was also suffering from seasonal flu (H3N2). They had been exposed to live poultry which also tested positive for H10N5.

Species already threatened with extinction are among those which have died due to bird flu in the past three years. The first deaths from the virus in mainland Antarctica have just been confirmed in skuas, highlighting a looming threat to penguin colonies whose eggs and chicks skuas prey on. Humboldt penguins have already been killed by the virus in Chile.

A colony of king penguins.
Remote penguin colonies are already threatened by climate change. AndreAnita/Shutterstock

How can we stem this tsunami of H5N1 and other avian influenzas? Completely overhaul poultry production on a global scale. Make farms self-sufficient in rearing eggs and chicks instead of exporting them internationally. The trend towards megafarms containing over a million birds must be stopped in its tracks.

To prevent the worst outcomes for this virus, we must revisit its primary source: the incubator of intensive poultry farms.

Diana Bell does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Read More

Continue Reading

Trending